400 related articles for article (PubMed ID: 17703416)
1. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination.
Jokinen S; Osterlund P; Julkunen I; Davidkin I
J Infect Dis; 2007 Sep; 196(6):861-7. PubMed ID: 17703416
[TBL] [Abstract][Full Text] [Related]
2. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
[TBL] [Abstract][Full Text] [Related]
3. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
5. Humoral and cellular immune response after measles vaccination in Taiwan.
Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
[TBL] [Abstract][Full Text] [Related]
6. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
[TBL] [Abstract][Full Text] [Related]
7. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
[TBL] [Abstract][Full Text] [Related]
8. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination.
Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA
J Infect Dis; 2005 Feb; 191(4):515-9. PubMed ID: 15655774
[TBL] [Abstract][Full Text] [Related]
9. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design.
Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Poland GA
Vaccine; 2007 Apr; 25(16):3090-100. PubMed ID: 17280755
[TBL] [Abstract][Full Text] [Related]
10. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children.
Glikmann G; Petersen I; Mordhorst CH
Dan Med Bull; 1988 Apr; 35(2):185-7. PubMed ID: 3359817
[TBL] [Abstract][Full Text] [Related]
12. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
[TBL] [Abstract][Full Text] [Related]
13. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
[TBL] [Abstract][Full Text] [Related]
14. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
[TBL] [Abstract][Full Text] [Related]
15. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART.
Belaunzarán-Zamudio PF; García-León ML; Wong-Chew RM; Villasís-Keever A; Cuellar-Rodríguez J; Mosqueda-Gómez JL; Muñoz-Trejo T; Escobedo K; Santos JI; Ruiz-Palacios GM; Sierra-Madero JG
Vaccine; 2009 Nov; 27(50):7059-64. PubMed ID: 19799846
[TBL] [Abstract][Full Text] [Related]
16. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG
Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218
[TBL] [Abstract][Full Text] [Related]
18. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
20. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.
LeBaron CW; Forghani B; Beck C; Brown C; Bi D; Cossen C; Sullivan BJ
J Infect Dis; 2009 Feb; 199(4):552-60. PubMed ID: 19113988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]